Role of etoposide-based chemotherapy in the treatment of patients with refractory or relapsing germ cell tumors
- 1 March 1985
- journal article
- research article
- Published by Elsevier in The American Journal of Medicine
- Vol. 78 (3) , 423-428
- https://doi.org/10.1016/0002-9343(85)90333-x
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- VP-16–213 and cisplatin in the treatment of patients with refractory germ cell tumorsAmerican Journal of Clinical Oncology, 1984
- The growing teratoma syndromeCancer, 1982
- ABVD chemotherapy in the treatment of Hodgkin's diseaseCancer Treatment Reviews, 1982
- VP-16-213 (etoposide): The mandrake root from Issyk-KulThe American Journal of Medicine, 1982
- VAB-6 Combination Chemotherapy in Disseminated Cancer of the TestisAnnals of Internal Medicine, 1981
- VAB–4 combination chemotherapy in the treatment of metastatic testis tumorsCancer, 1981
- VP-16–213 salvage therapy for refractory germinal neoplasmsCancer, 1980
- VP16-213 as a single agent in advanced testicular tumorsPublished by Elsevier ,1980
- COMBINATION CHEMOTHERAPY WITH CIS-DICHLORODIAMMINEPLATINUM(II) AND ADRIAMYCIN FOR TESTICULAR CANCER REFRACTORY TO VINBLASTINE PLUS BLEOMYCIN1978